Literature DB >> 6443347

Quantification of C1-inhibitor functional activities by immunodiffusion assay in plasma of patients with hereditary angioedema--evidence of a functionally critical level of C1-inhibitor concentration.

P J Späth, B Wüthrich, R Bütler.   

Abstract

The relationship of C1-inhibitor (C1-INH) concentration and apparent functional activity was investigated in 111 plasma samples from 21 patients with the common form of hereditary angioedema (HAE). Functional C1-INH was analyzed by means of a modified version of immunodiffusion assay. Down to a C1-INH level of approximately 0.075 g/l (38% of normal) apparent C1-INH functions were found within the normal range, while below this level functional adequacy of C1-INH could no longer be ascertained. When C4 concentrations, considered to reflect approximately functional C1-INH, were related to C1-INH antigen levels of individual samples, a relationship emerged which was identical to that between C1-INH concentration and apparent function. No attacks of edema could be associated with C1-INH concentrations above 0.075 g/l, while it was possible to associate attacks with concentrations below this level. In experiments where patient plasma and normal plasma were mixed in various ratios or where HAE plasma was replaced by purified C1-INH, an increase in C1-INH antigen to concentrations of 0.06-0.08 g/l was followed by a sharp rise in apparent functions to normal values. The rise of functional C1-INH became moderate when C1-INH antigen further increased. The results supported the idea of a functionally critical level of C1-INH in the common form of HAE.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6443347     DOI: 10.1159/000467830

Source DB:  PubMed          Journal:  Complement        ISSN: 0253-5076


  22 in total

1.  Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond.

Authors:  Angelo Agostoni; Emel Aygören-Pürsün; Karen E Binkley; Alvaro Blanch; Konrad Bork; Laurence Bouillet; Christoph Bucher; Anthony J Castaldo; Marco Cicardi; Alvin E Davis; Caterina De Carolis; Christian Drouet; Christiane Duponchel; Henriette Farkas; Kálmán Fáy; Béla Fekete; Bettina Fischer; Luigi Fontana; George Füst; Roberto Giacomelli; Albrecht Gröner; C Erik Hack; George Harmat; John Jakenfelds; Mathias Juers; Lajos Kalmár; Pál N Kaposi; István Karádi; Arianna Kitzinger; Tímea Kollár; Wolfhart Kreuz; Peter Lakatos; Hilary J Longhurst; Margarita Lopez-Trascasa; Inmaculada Martinez-Saguer; Nicole Monnier; István Nagy; Eva Németh; Erik Waage Nielsen; Jan H Nuijens; Caroline O'grady; Emanuela Pappalardo; Vincenzo Penna; Carlo Perricone; Roberto Perricone; Ursula Rauch; Olga Roche; Eva Rusicke; Peter J Späth; George Szendei; Edit Takács; Attila Tordai; Lennart Truedsson; Lilian Varga; Beáta Visy; Kayla Williams; Andrea Zanichelli; Lorenza Zingale
Journal:  J Allergy Clin Immunol       Date:  2004-09       Impact factor: 10.793

Review 2.  HAE Pathophysiology and Underlying Mechanisms.

Authors:  Bruce L Zuraw; Sandra C Christiansen
Journal:  Clin Rev Allergy Immunol       Date:  2016-10       Impact factor: 8.667

Review 3.  Aspects of C1-inhibitor biochemistry and pathophysiology.

Authors:  T K Nilsson
Journal:  Clin Rheumatol       Date:  1987-09       Impact factor: 2.980

Review 4.  Clinical utility of complement assessment.

Authors:  A E Ahmed; J B Peter
Journal:  Clin Diagn Lab Immunol       Date:  1995-09

5.  Acquired C1 inhibitor (C1-INH) deficiency type II. Replacement therapy with C1-INH and analysis of patients' C1-INH and anti-C1-INH autoantibodies.

Authors:  J Alsenz; J D Lambris; K Bork; M Loos
Journal:  J Clin Invest       Date:  1989-06       Impact factor: 14.808

6.  Population pharmacokinetics of recombinant human C1 inhibitor in patients with hereditary angioedema.

Authors:  Colm Farrell; Siobhan Hayes; Anurag Relan; Edwin S van Amersfoort; Rienk Pijpstra; C Erik Hack
Journal:  Br J Clin Pharmacol       Date:  2013-12       Impact factor: 4.335

Review 7.  A Decade of Change: Recent Developments in Pharmacotherapy of Hereditary Angioedema (HAE).

Authors:  Konrad Bork
Journal:  Clin Rev Allergy Immunol       Date:  2016-10       Impact factor: 8.667

Review 8.  "Nuts and Bolts" of Laboratory Evaluation of Angioedema.

Authors:  Henriette Farkas; Nóra Veszeli; Erika Kajdácsi; László Cervenak; Lilian Varga
Journal:  Clin Rev Allergy Immunol       Date:  2016-10       Impact factor: 8.667

9.  Acquired angioedema in B cell lymphoproliferative disease: A retrospective case series.

Authors:  Alex Wonnaparhown; Alexandra Stefanovic; Patricia Lugar; Haley P Hostetler
Journal:  Clin Exp Immunol       Date:  2021-10-11       Impact factor: 4.330

Review 10.  Current and Prospective Targets of Pharmacologic Treatment of Hereditary Angioedema Types 1 and 2.

Authors:  Lauré M Fijen; Konrad Bork; Danny M Cohn
Journal:  Clin Rev Allergy Immunol       Date:  2021-01-09       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.